Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2021 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...